1) Today’s News Headlines
Eli Lilly just got FDA clearance for a multi-dose Zepbound pen—potentially a convenience win for patients navigating long-term treatment. (lilly.com)
Meanwhile, Novo Nordisk’s next-gen CagriSema underperformed tirzepatide in a head-to-head trial, intensifying the obesity-medicine “arms race.” (theguardian.com)
And a new Cochrane review throws cold water on intermittent fasting hype: it’s not meaningfully better than standard dieting for weight loss. (pubmed.ncbi.nlm.nih.gov)
2) Today’s Top Stories
Zepbound gets a multi-dose KwikPen: what changes for patients?
Eli Lilly announced the FDA approved a label expansion for Zepbound (tirzepatide) to include a four-dose, single-patient-use KwikPen—one device for a month of weekly injections. LillyDirect is accepting prescriptions, with self-pay pricing starting at $299/month for the 2.5 mg starting dose (higher doses priced higher, with program terms that may reduce certain doses). (lilly.com)
Why it matters: Device choice can improve adherence—less friction often means better continuity, especially in the “messy middle” months.
Source: Eli LillyDirect announcement (lilly.com)
Novo’s CagriSema loses to tirzepatide in head-to-head trial
In coverage of Novo Nordisk’s REDEFINE 4 comparison study, CagriSema (semaglutide + cagrilintide, an amylin analog) did not match tirzepatide on weight loss over 84 weeks, failing a non-inferiority goal. Reports describe weight loss figures around ~20.2% vs ~23.6% (treatment policy estimand) and “up to” 23% vs 25.5% in other analyses/coverage, underscoring how results can look different depending on how you count dropouts and adherence. (statnews.com)
Why it matters: The next wave of obesity meds is being judged against a very high bar; “new” doesn’t automatically mean “better.”
Source: STAT News coverage (statnews.com)
FDA flags risks of unapproved/compounded GLP-1s as enforcement tightens
A report citing FDA actions and local public health fallout highlights ongoing concerns about compounded “versions” of GLP-1s. The FDA has been explicit that compounded GLP-1s are not FDA-approved and should generally be reserved for cases where an FDA-approved drug can’t meet a patient’s medical need, with additional warnings about quality, shipping/storage, and fraudulent products. (fda.gov)
Why it matters: If cost or access pressures push people toward gray-market options, the safety tradeoffs can be real—and preventable.
Source: FDA: concerns with unapproved GLP-1 drugs used for weight loss (fda.gov)
3) Deep Dive (Tuesday — Science Simplified)
Intermittent fasting isn’t “bad”—it’s just not special (per Cochrane)
The study: A 2026 Cochrane Database of Systematic Reviews paper evaluated intermittent fasting (time-restricted eating, alternate-day fasting, periodic fasting) in adults with overweight/obesity, comparing it with regular dietary advice and with no intervention/wait list. (pubmed.ncbi.nlm.nih.gov)
What they found (in plain English):
- Compared with “regular dietary advice,” intermittent fasting produced little to no difference in weight loss and quality of life (evidence certainty described as low/uncertain in key outcomes). (pubmed.ncbi.nlm.nih.gov)
- Compared with doing nothing/wait list, it likely produces little to no difference as well (and the evidence around harms/adverse events is uncertain). (pubmed.ncbi.nlm.nih.gov)
- Most included studies were short-term (up to 12 months), limiting what we can say about long-term maintenance. (pubmed.ncbi.nlm.nih.gov)
Myth-busting (kindly):
The myth is that fasting “switches on” a unique fat-burning mode that beats calories. The more boring truth is: fasting tends to work when it helps you eat fewer calories consistently—not because it’s metabolically magical. This is why people can see success on fasting or on a conventional structure (3 meals, higher protein, calorie awareness) when adherence is high. (pubmed.ncbi.nlm.nih.gov)
Practical takeaways you can use today:
- Pick the structure you can repeat on your worst Tuesday. If a 10–12 hour eating window reduces grazing without triggering rebound hunger, it’s a tool. If it causes “white-knuckle” restriction → nighttime overeating, it’s not your tool. (pubmed.ncbi.nlm.nih.gov)
- Anchor with protein + fiber, not just a clock. Regardless of timing, meals built around protein and high-fiber plants tend to improve fullness and reduce impulsive snacking (the driver is usually appetite control, not willpower).
- If you’re on a GLP-1: fasting rules may be unnecessary. Many patients do best with steady, smaller meals to minimize nausea and keep protein intake adequate—your medication already changes appetite biology.
4) Quick Hits
- If you self-pay for Zepbound, read LillyDirect’s refill timing terms carefully—some offers depend on refilling within a specific window. (lilly.com)
- Novo’s CagriSema news is a reminder to read trial design details (open-label vs blinded, estimands, dropouts) before comparing “% weight loss” headlines. (statnews.com)
- FDA reiterates: compounded drugs are not FDA-approved, and quality issues (like warm shipments) are a known concern for injectable GLP-1s. (fda.gov)
- If you’re considering “research use only” peptides sold online: FDA explicitly warns against products illegally marketed this way. (fda.gov)
- Intermittent fasting fans: you don’t need to quit—just drop the expectation that it outperforms other diets automatically. (pubmed.ncbi.nlm.nih.gov)
- Clinician note: the Cochrane review highlights a gap in participant satisfaction data—future studies need more than just scale weight. (pubmed.ncbi.nlm.nih.gov)
5) By The Numbers
22 randomized trials, 1,995 participants — that’s the evidence base behind the new Cochrane review on intermittent fasting in adults with overweight/obesity. (pubmed.ncbi.nlm.nih.gov)
What it means: Big enough to reduce “one-study hype,” but still limited by short follow-up and variable study quality. (pubmed.ncbi.nlm.nih.gov)
Why you should care: If a plan feels miserable, you’re not “failing the plan”—the plan may simply not be more effective than alternatives you’d adhere to better.
6) Ask The Community
If you’ve tried intermittent fasting: did it reduce decision fatigue (easier), or did it increase rebound eating (harder)—and what eating window (if any) felt most sustainable?
7) Tomorrow’s Preview
Community Voices: a real-world strategy stack (food, movement, and mindset) that helped someone keep going after a plateau—plus the one habit they’d restart first if they had to begin again.